In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for ...

Ipsen S.A. delivered strong 1Q26 results, with 22.6% CER revenue growth and rare disease revenues up 125% CER, reinforcing ...

The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

This is Ipsen’s second acquisition this week, following its blockbuster Kartos buyout on 29 June.

The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen’s oncology pipeline.

Core operating margin of 32.4%, a decline of 1.6% points, driven mainly by enhanced R&D investment. An unchanged IFRS operating margin of 19.2% Upgraded 2024 financial guidance: total-sales growth ...

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales ...

Ipsen has delivered a 100.7% total return over the past five years, yet there is a clear split in what the valuation work is ...

Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine ...

June 29 (Reuters) - Ipsen will buy U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with a late-stage blood cancer treatment, the French biotech company said on Monday.

A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...